A chondromimetic microsphere for in situ spatially controlled chondrogenic differentiation of human mesenchymal stem cells

J Control Release. 2014 Apr 10:179:42-51. doi: 10.1016/j.jconrel.2014.01.023. Epub 2014 Jan 31.

Abstract

Human mesenchymal stem cells (hMSCs) have been identified as a viable cell source for cartilage tissue engineering. However, to undergo chondrogenic differentiation hMSCs require growth factors, in particular members of the transforming growth factor beta (TGF-β) family. While in vitro differentiation is feasible through continuous supplementation of TGF-β3, mechanisms to control and drive hMSCs down the chondrogenic lineage in their native microenvironment remain a significant challenge. The release of TGF-β3 from an injectable microsphere composed of the cartilage-associated extracellular matrix molecule hyaluronan represents a readily translatable approach for in situ differentiation of hMSCs for cartilage repair. In this study, chondromimetic hyaluronan microspheres were used as a growth factor delivery source for hMSC chondrogenesis. Cellular compatibility of the microspheres (1.2 and 14.1 μm) with hMSCs was shown and release of TGF-β3 from the most promising 14.1 μm microspheres to control differentiation of hMSCs was evaluated. Enhanced accumulation of cartilage-associated glycosaminoglycans by hMSCs incubated with TGF-β3-loaded microspheres was seen and positive staining for collagen type II and proteoglycan confirmed successful in vitro chondrogenesis. Gene expression analysis showed significantly increased expression of the chondrocyte-associated genes, collagen type II and aggrecan. This delivery platform resulted in significantly less collagen type X expression, suggesting the generation of a more stable cartilage phenotype. When evaluated in an ex vivo osteoarthritic cartilage model, implanted hMSCs with TGF-β3-loaded HA microspheres were detected within cartilage fibrillations and increased proteoglycan staining was seen in the tissue. In summary, data presented here demonstrate that TGF-β3-bound hyaluronan microspheres provide a suitable delivery system for induction of hMSC chondrogenesis and their use may represent a clinically feasible tissue engineering approach for the treatment of articular cartilage defects.

Keywords: Chondrogenesis; Delivery vehicle; Mesenchymal stem cell; Microspheres; Osteoarthritis; Tissue engineering.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aggrecans / genetics
  • Aggrecans / metabolism
  • Animals
  • Biomimetics*
  • Cell Differentiation / drug effects*
  • Cell Line
  • Chondrocytes / drug effects*
  • Chondrocytes / metabolism
  • Chondrocytes / transplantation
  • Chondrogenesis / drug effects*
  • Collagen Type II / genetics
  • Collagen Type II / metabolism
  • Collagen Type X / metabolism
  • Dose-Response Relationship, Drug
  • Drug Carriers*
  • Gene Expression Regulation
  • Humans
  • Hyaluronic Acid / metabolism
  • Mesenchymal Stem Cell Transplantation
  • Mesenchymal Stem Cells / drug effects*
  • Mesenchymal Stem Cells / metabolism
  • Microspheres
  • Osteoarthritis, Knee / metabolism
  • Osteoarthritis, Knee / pathology
  • Osteoarthritis, Knee / therapy
  • Phenotype
  • Time Factors
  • Tissue Engineering*
  • Transforming Growth Factor beta3 / pharmacology*
  • Transforming Growth Factor beta3 / toxicity
  • Young Adult

Substances

  • Aggrecans
  • Collagen Type II
  • Collagen Type X
  • Drug Carriers
  • TGFB3 protein, human
  • Transforming Growth Factor beta3
  • Hyaluronic Acid